ArticleCentral-European journal of immunology2026
N6-methyladenosine modification of CBLB affects LPS-induced endoplasmic reticulum stress in alveolar epithelial cells.
Article in Central-European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lung injury (ALI) is defined as an acute hypoxic respiratory insufficiency that arises from injury to alveolar epithelial cells. The suppression of endoplasmic reticulum stress (ERS) was reported to protect against ALI. This study investigated the mechanism of N6-methyladenosine (m6A)-modified Casitas B lymphoma-b (CBLB) on ERS in lipopolysaccharide (LPS)-induced type II alveolar epithelial cells (AECIIs). Material and methods: AECII viability was evaluated via Cell Counting Kit-8 (CCK-8). The reactive oxygen species (ROS) level was examined via an ROS kit. TUNEL staining was applied to assay apoptosis. The levels of CBLB, LIM domain kinase 1 (LIMK1), methyltransferase-like 14 (METTL14), and ERS-related proteins were assessed by western blot and immunofluorescence. The ubiquitination level of LIMK1 was analyzed using immunoprecipitation. The interrelationship between CBLB and LIMK1 was identified via Co-IP. The m6A modification of CBLB was analyzed through MeRIP. The binding of METTL14 to the CBLB mRNA was verified by RIP. Results: CBLB facilitated the ubiquitination and degradation of LIMK1. The suppressive action of upregulated CBLB on apoptosis and ERS in LPS-induced AECIIs was reversed by LIMK1 overexpression. METTL14 reduced the stability of CBLB mRNA in a manner dependent on m6A methylation. CBLB knockdown reversed the inhibitory effects of METTL14 silencing on apoptosis and ERS in LPS-stimulated AECIIs. Conclusions: METTL14-mediated m6A modification of CBLB impaired the mRNA stability of CBLB to block the degradation of LIMK1, which promoted ERS in LPS-induced AECIIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.